Eclipse Regenesis

Eclipse Regenesis, Inc. is developing the first restorative therapy to address pediatric and adult Short Bowel Syndrome (SBS), a malabsorption disorder caused by a loss of functional small intestine. Current chronic therapies for SBS include parenteral nutrition, daily medications, and intestinal surgery, which come at a staggering average 5-year cost of $1.6M per patient. Via distraction enterogenesis, the Eclipse XL1 System can harness the body’s own tissue regenerative capabilities to produce a new, fully functional intestine in vivo. Together with the world’s leading clinical thought leaders in SBS, our team is passionate about pioneering our restorative therapy to a disease state that today has no cure.